<DOC>
	<DOCNO>NCT02175784</DOCNO>
	<brief_summary>The purpose study assess efficacy ( superiority placebo ) ipragliflozin base change HbA1C , well safety , patient type 2 diabetes mellitus combination insulin preparation daily 16 week . The long-term ( 52 week ) safety persistence efficacy also evaluate .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Ipragliflozin Combination With Insulin Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This study consist two part . First part placebo-controlled multicenter , double-blind , parallel group study , subject receive ipragliflozin placebo daily combination insulin preparation 16 week . Second part multicenter , open-label period ( 36 week ) placebo group . The dose ipragliflozin double combination insulin preparation second part .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Subject diagnose type 2 diabetes mellitus least 12 week ( 84 day ) signing informed consent . Subject take constant dosage administration insulin preparation 6 week ( 42 day ) Subject HbA1C value 7.5 10.0 % Visit 2 difference HbA1C value within Â± 1.0 % Visit 1 Visit 2 Subject body mass index ( BMI ) 20.0 45.0 kg/m2 Subject type 1 diabetes mellitus Subject proliferative diabetic retinopathy Subject history clinically significant renal disease renovascular occlusive disease , nephrectomy and/or renal transplant Subject history recurrent urinary tract infection ( three time within 24 week obtain informed consent ) Subject symptomatic urinary tract infection symptomatic genital infection Subject chronic disease require continuous use adrenocortical steroid immunosuppressant ( oral medication , injection , inhalation ) Subject history cerebral vascular attack , unstable angina , myocardial infarction , vascular intervention , heart disease ( NYHA Class IIIIV ) within 1 year ( 52 week ) prior Visit 1 Subject unstable psychiatric disorder Female subject currently pregnant lactating , possibly pregnant Male premenopausal female subject use appropriate contraception study Subject severe infection , perioperative , serious trauma Subject drug addiction alcohol abuse Subject history malignant tumor ( except receive treatment malignant tumor least 5 year informed consent acquisition consider recurrence ) Subject history allergy ipragliflozin and/or similar drug ( study drug possess SGLT 2 inhibitory action ) Subject participate another clinical study , post marketing study , medical equipment study within 12 week ( 84 day ) provide write informed consent , currently participate study Subject unable , unwilling adhere compliance hospital visit dose instruction specify study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Blood glucose</keyword>
	<keyword>insulin</keyword>
	<keyword>ipragliflozin</keyword>
	<keyword>SGLT2 inhibitor</keyword>
</DOC>